問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Neurology

更新時間：2023-09-19

巫錫霖
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

2Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

巫錫霖

List

20Cases

2007-06-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2007-12-04 - 2010-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-01-01 - 2012-07-31

Phase III

Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo

  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    LY450139

Participate Sites
5Sites

Terminated5Sites

2010-01-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-03-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2009-08-01 - 2012-07-31

Phase III

Effect of Passive Immunization on the Progression of Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo

  • Condition/Disease

    Alzheimer's disease

  • Test Drug

    Solanezumab (LY2062430)

Participate Sites
10Sites

Terminated10Sites

2019-12-01 - 2020-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy

  • Condition/Disease

    Drug-Resistant Epilepsy/Focal-Onset Seizures

  • Test Drug

    Padsevonil

Participate Sites
8Sites

Terminated8Sites

2013-01-01 - 2015-12-31

Phase III

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease

  • Condition/Disease

    Alzeheimer's Disease

  • Test Drug

    LMTM

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

楊玉婉
China Medical University Hospital

Division of Neurology

2016-12-31 - 2023-12-31

Phase III

A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease

  • Condition/Disease

    Prodromal Alzheimer's Disease

  • Test Drug

    Solanezumab (LY2062430)

Participate Sites
10Sites

Terminated9Sites

2017-06-01 - 2019-12-31

Phase III

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    Elenbecestat (E2609)

Participate Sites
13Sites

Terminated11Sites

胡朝榮
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Neurology

劉景寬
Kaohsiung Municipal Gangshan Hospital

未分科

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB